Literature DB >> 19467548

Familial amyloid polyneuropathy: a clinico-pathologic study.

Gérard Said1, Violaine Planté-Bordeneuve.   

Abstract

UNLABELLED: In familial amyloid polyneuropathy (FAP), destruction of nerve fibres is related to accumulation of mutated transthyretin (mTTR) derived amyloid deposits (AD) in the endoneurium. Liver transplantation (LT), which removes the main source of mTTR, does not prevent deterioration of the clinical condition in all recipients.
MATERIAL AND METHODS: We evaluated the distribution of AD in the central and peripheral nervous system in order to better understand the pathophysiology of FAP and the potential role of lesions of nerve blood vessels and of mTTR released by choroid plexuses (CP). Forty nerve biopsy specimens and 3 autopsy cases, including 7 patients who underwent liver transplantation, all from patients with symptomatic FAP and DNA mutation of the TTR gene, were included.
RESULTS: Patients were ranged into three categories: MORPHOLOGICAL CHANGES: Amyloid predominated around endoneurial capillaries in 37 patients, with occlusion/destruction of endoneurial capillaries in 15 nerves at late stages of the disease. Post-mortem examination showed amyloid in choroid plexuses and perivascular spaces in the brain and around blood vessels penetrating the endoneurium, following arachnoid and connective tissue septae. Destruction of endoneurial blood vessels is a late event in the natural course of FAP. Morphological findings were similar in patients who underwent liver transplantation and in those who did not. The distribution of amyloid in areas communicating with the subarachnoid space suggests that mutated TTR released in the CSF may move to the endoneurial fluid and accumulate in peripheral nerves, accounting for lack of efficacy of liver transplantation in some individuals.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19467548     DOI: 10.1016/j.jns.2009.05.001

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  10 in total

1.  Progression of transthyretin amyloid neuropathy after liver transplantation.

Authors:  Juris J Liepnieks; Lucy Q Zhang; Merrill D Benson
Journal:  Neurology       Date:  2010-07-27       Impact factor: 9.910

2.  Tafamidis for a Transplant Patient with Transthyretin Amyloid Polyneuropathy.

Authors:  Jesús Romero-Imbroda; Teresa Sagrario-Fustero; Clementina Del Canto-Pérez
Journal:  J Clin Neurol       Date:  2017-09-04       Impact factor: 3.077

3.  Transthyretin amyloid neuropathy has earlier neural involvement but better prognosis than primary amyloid counterpart: an answer to the paradox?

Authors:  Adam J Loavenbruck; Wolfgang Singer; Michelle L Mauermann; Paola Sandroni; P James B Dyck; Morie Gertz; Christopher J Klein; Phillip A Low
Journal:  Ann Neurol       Date:  2016-07-25       Impact factor: 10.422

4.  In vivo detection of nerve injury in familial amyloid polyneuropathy by magnetic resonance neurography.

Authors:  Jennifer Kollmer; Ernst Hund; Benjamin Hornung; Ute Hegenbart; Stefan O Schönland; Christoph Kimmich; Arnt V Kristen; Jan Purrucker; Christoph Röcken; Sabine Heiland; Martin Bendszus; Mirko Pham
Journal:  Brain       Date:  2014-12-18       Impact factor: 13.501

5.  Transthyretin-Related Familial Amyloid Polyneuropathy (TTR-FAP): A Single-Center Experience in Sicily, an Italian Endemic Area.

Authors:  Anna Mazzeo; Massimo Russo; Gianluca Di Bella; Fabio Minutoli; Claudia Stancanelli; Luca Gentile; Sergio Baldari; Scipione Carerj; Antonio Toscano; Giuseppe Vita
Journal:  J Neuromuscul Dis       Date:  2015-07-22

6.  Neuropathologic analysis of Tyr69His TTR variant meningovascular amyloidosis with dementia.

Authors:  Jennifer L Ziskin; Michael D Greicius; Wan Zhu; Anna N Okumu; Christopher M Adams; Edward D Plowey
Journal:  Acta Neuropathol Commun       Date:  2015-07-10       Impact factor: 7.801

7.  Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy.

Authors:  Teresa Coelho; Luis F Maia; Ana Martins da Silva; Márcia W Cruz; Violaine Planté-Bordeneuve; Ole B Suhr; Isabel Conceiçao; Hartmut H-J Schmidt; Pedro Trigo; Jeffery W Kelly; Richard Labaudinière; Jason Chan; Jeff Packman; Donna R Grogan
Journal:  J Neurol       Date:  2013-08-22       Impact factor: 4.849

8.  Epidemiology of transthyretin-associated familial amyloid polyneuropathy in the Majorcan area: Son Llàtzer Hospital descriptive study.

Authors:  Juan Buades Reinés; Tomás Ripoll Vera; Mercedes Uson Martín; Hernán Andréu Serra; Ma Margarita Company Campins; José Miguel Diéguez Millán; Cristina Gallego Lezaun; Manuel Raya Cruz
Journal:  Orphanet J Rare Dis       Date:  2014-02-26       Impact factor: 4.123

Review 9.  Recent advances in transthyretin amyloidosis therapy.

Authors:  Mitsuharu Ueda; Yukio Ando
Journal:  Transl Neurodegener       Date:  2014-09-13       Impact factor: 8.014

10.  The Temporal Profiles of Changes in Nerve Excitability Indices in Familial Amyloid Polyneuropathy.

Authors:  Hsing-Jung Lai; Ya-Wen Chiang; Chih-Chao Yang; Sung-Tsang Hsieh; Chi-Chao Chao; Ming-Jen Lee; Chung-Chin Kuo
Journal:  PLoS One       Date:  2015-11-03       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.